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Background: Leflunomide is the prodrug of the disease modifying antirheumatic metabolite A77 1726.
More than 50% of patients withdraw from leflunomide treatment within one year, mainly because of
adverse drug reactions. Therapeutic drug monitoring of A77 1726 may be useful in predicting the efficacy
of leflunomide treatment.
Objective: To study the relation between A77 1726 steady state serum concentrations and disease activity
using the 28 joint (DAS28) response.
Methods: Outpatients with rheumatoid arthritis on a stable leflunomide dose for .4 months were
included. DAS28 score and adverse drug reactions were recorded. Blood samples were taken for
determination of A77 1726 concentrations. The primary end point was the relation of serum A77 1726
concentrations with DAS28 response category
Results: Serum A77 1726 concentrations were determined in 52 patients. A receiver operating
characteristic (ROC) curve showed an area under the curve (AUC) of 0.73 (95% confidence interval, 0.54
to 0.93) (p,0.05). The sensitivity exceeded 99% at concentrations below 16 mg/l. DAS28 values at the
point of sampling showed no relation with A77 1726 concentrations (AUC of the ROC curve = 0.50 (0.33
to 0.67) (NS)).
Conclusions: A77 1726 steady state serum concentrations show a relation with DAS28 response.
Determination of serum A77 1726 concentrations in patients with insufficient response to treatment may
help when decisions have to be made about continuation of treatment or dose adjustment.
L
eflunomide is a disease modifying antirheumatic drug
(DMARD) of the isoxazole class. After oral administration
it is rapidly, non-enzymatically, and completely converted
into its active metabolite A77 1726 (2-cyano-3-hydroxy-N-
(4-trifluoromethylphenyl)-crotonamide).1 A77 1726 has anti-
rheumatic activity through inhibition of the enzyme dihydro-
orotate dehydrogenase (DHODH). DHODH is a key enzyme in
the de novo production of pyrimidines in T lymphocytes, a
process essential for T lymphocyte proliferation. A77 1726
has a long mean plasma half life of 15.7 days (range 14 to 18)
in patients with rheumatoid arthritis.1–3
Leflunomide has antirheumatic activity comparable with
methotrexate and sulfasalazine.4 Although an antirheumatic
effect can be observed within a few weeks, in some patients
onset of efficacy takes up to six months.5 Moreover, there is a
high incidence of adverse events, possibly explained by the
uniform dosing schedule with only few options for dose
adjustment. These factors limit the efficacy of leflunomide in
populations of patients with rheumatoid arthritis.6–8 Thus
optimisation of leflunomide treatment is warranted.
Therapeutic drug monitoring based on steady state
A77 1726 serum concentrations may allow individualised
dose adjustment and consequently increase the clinical
effectiveness. In phase II pharmacokinetic population mod-
elling studies, a relation between steady state A77 1726
serum concentrations of less than 13 mg/l and a reduced
probability of clinical success has been described.9
In this study we investigated the relation between
rheumatoid arthritis disease activity and the steady state
serum concentrations of A77 1726 in patients treated with
leflunomide.
METHODS
Patients
Patients with rheumatoid arthritis, visiting the outpatient
departments of rheumatology in the four participating
centres in the period from January 2003 to January 2004,
and on fixed doses of leflunomide for at least the previous
four months, were asked to participate. After obtaining
written informed consent, a single venous blood sample was
taken for determination of A77 1726. We also recorded
patient demographic data, disease characteristics, drug
treatment, and the four variables required for calculating
the 28 joint disease activity score (DAS28): tender joint
count, swollen joint count, erythrocyte sedimentation rate,
and a 100 mm visual analogue scale for general health status
as estimated by the patient. The DAS28 score at the time of
starting on leflunomide was retrieved from the patients’
records. All DAS28 variables were scored for each patient by
the same rheumatologist at each visit. DAS28 was calculated
from the four variables at the end of the study to prevent any
influence of the DAS28 score on treatment decisions.
Abbreviations: AUC, area under the curve; DAS28, 28 joint disease
activity score; DHODH, dihydro-orotate dehydrogenase; DMARD,
disease modifying antirheumatic drug; EULAR, European League
Against Rheumatism; ROC, receiver operating characteristic
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Exclusion criteria were participation in another study and
concomitant use of daily doses of .10 mg prednisone
equivalents or pharmacokinetically interacting drugs.
Interacting drugs were detected by checking medication
histories for prescription of rifampicin, activated charcoal, or
cholestyramine.3
As non-compliance with leflunomide treatment influences
exposure to leflunomide and therefore the steady state serum
concentrations of A77 1726, an effort was made assess
treatment compliance. For this purpose the patients’ local
pharmacies were asked for leflunomide refill data. Tracking
of virtually complete prescription data is possible because in
the Netherlands patients usually register with one pharmacy
only, and local pharmacies keep a computerised record of all
prescriptions dispensed. The refill rate is calculated from the
refill data as:
[n tablets delivered/n days since leflunomide start] / n
prescribed tablets per day
Refill rates under 1.0 represent underconsumption, above 1.0
overconsumption. Refill rates from 0.9 to 1.1 were categorised
as good compliance.10
The human medical ethics research committee approved
the study.
Determination of A77 1726
Blood samples were analysed for A77 1726 by a validated
high pressure liquid chromatographic method.11 We calcu-
lated mean (SD) serum A77 1726 concentration and the
percentage of patients with a steady state A77 1726
concentration of ,13 mg/l, the previously reported cut off
concentration for optimal clinical success.9
End points
The primary end point was to determine the relation between
serum A77 1726 concentration and the DAS28 responder
category. The DAS28 responder category was determined by
comparing the DAS28 score at the start of leflunomide
treatment with score at the point of sampling. Responders
were categorised according to the EULAR criteria.12 13 In
clinical rheumatology practice a moderate response is
insufficient as a treatment goal, so for our analyses we
compared a good response with moderate or no response. The
null hypothesis for this end point was that low A77 1726
serum concentrations will predict a poorer response. For
determination of this end point we included all patients for
whom we had available the serum A77 1726 concentrations,
DAS28 at the start of leflunomide treatment, and DAS28 at
the point of sampling. As disease activity is directly
influenced by concomitant use of DMARDs, patients on
leflunomide in combination with other DMARDs were
excluded from this analysis.
The secondary end point was to determine the relation
between serum A77 1726 concentration and disease activity
at the point of sampling. DAS28 was categorised into low
((3.2) or high (.3.2) disease activity, according to the
EULAR criteria.12 13 The null hypothesis for this end point was
that lower A77 1726 serum concentrations are associated
with high disease activity. All patients in whom serum
A77 1726 concentrations and the DAS28 score at the point of
sampling were available were included for analysis of this
end point. As for the primary end point, concomitant use of
DMARDs other than leflunomide was an exclusion criterion
for this analysis.
Statistical analysis
SPSS 12.0.1 for Windows was used for data collection, data
validation, data selection, and statistical analysis.
Kolmogorov–Smirnov analysis was used to test for normality
of the distribution of serum A77 1726 concentrations per
dose group. Differences in mean serum A77 1726 concentra-
tions between the leflunomide dose groups were studied
using Student’s t test. Receiver operator characteristics (ROC)
curves and x2 analysis were used to determine the relation of
serum A77 1726 concentrations with disease activity and
DAS28 responder category, respectively. The relation between
disease activity or response and corticosteroid or NSAID use
was tested using x2 analysis.
RESULTS
The steady state A77 1726 concentration was determined in
52 patients (table 1). These showed large interindividual
variability, ranging from 3 to 150 mg/l (fig 1). In six patients
(12%), A77 1726 concentrations were ,13 mg/l; all these
patients were on daily leflunomide doses of 20 mg. In two
patients, serum A77 1726 concentrations exceed 100 mg/l;
both these were on 20 mg leflunomide daily. The mean (SD)
serum A77 1726 concentrations in patients on 10 and 20 mg
doses were 33 (24) mg/l (range 15 to 98) and 42 (35) mg/l
(range 3 to 150), respectively. The difference in mean serum
A77 1726 concentrations in the two dose groups did not
reach statistical significance (p=0.12).
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Figure 1 Box and whisker plots for serum A77 1726 concentrations
with daily doses of 10 mg and 20 mg leflunomide. Circles indicate
outlying values.
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Figure 2 ROC (receiver operating characteristic) curve for the 28 joint
disease activity score response versus A77 1726 concentration
(AUC=0.73 (95% confidence interval, 0.54 to 0.93)). The dashed line is
the reference. AUC, area under the curve.
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Seventy one per cent of the patients showed compliance,
with refill rates between 0.9 and 1.1. Refill rates varied
between 0.56 and 1.35, with 22% of the population having
a rate below 0.9 and 7% having a rate above 1.1. Refill rate
and A77 1726 serum concentration were not correlated
(r=0.008). Patients with A77 1726 concentrations ,13 mg/l
or .100 mg/l showed compliance, with refill rates between
0.93 and 1.06.
Primary end point: DAS28 response v A77 1726
concentration
DAS28 values were recorded at the start of leflunomide
treatment and at the point of sampling in 25 patients
(table 2). Figure 2 shows the ROC curve for DAS28 response
in relation to the A77 1726 concentration. The area under the
curve is 0.73 (95% confidence interval (CI), 0.54 to 0.93)
(p,0.05). At a serum concentration of 18 mg/l A77 1726,
sensitivity was 90.9%. At the 16 mg/l level the sensitivity was
100%; that is, patients with a good response according to the
EULAR criteria were not present below this serum concen-
tration of A77 1726.
Table 3 shows the 262 table for test results (positive test:
A77 1726 serum concentration >16 mg/l) versus response
(positive response: good responder according to DAS28
criteria). In x2 analysis there was significant dependence of
DAS28 response on A77 1726 serum concentration, using
16 mg/l as the cut off point for the dichotomy (p=0.02).
The positive predictive value of a high A77 1726 serum
concentration (>16 mg/l) for a good response according to
DAS28 criteria was 56% (95% CI, 33% to 79%); that is, in 56%
of the patients a serum A77 1726 concentration of 16 mg/l or
more correctly predicted that they would respond well. The
negative predictive value of a low A77 1726 serum concen-
tration (,16 mg/l and ‘‘no response’’) was 100% (the 95%
confidence interval was not calculated as there were no good
responders at serum A77 1726 concentrations of less than
16 mg/l); thus serum A77 1726 concentrations of less than
16 mg/l were associated with non-response in all cases where
such low concentrations were found. The likelihood ratio for
a positive test result—that is, the ratio of a positive test result
(A77 1726 serum concentration >16 mg/l) for good versus
moderate or non-response—was 1.9 (95% CI, 1.1 to 2.9). The
likelihood ratio for a negative test result—that is, the ratio of
a negative test result (A77 1726 serum concentration
,16 mg/l) for good versus moderate or non-response—was
0 (0.0 to 1.5).
The DAS28 response was not significantly related to
corticosteroid use (p.0.1) or NSAID use (p.0.1).
Secondary end point: DAS28 versus A77 1726
concentration
Data from 45 of the 52 patients included in the study were
used for this end point. Five patients were excluded because
of combination treatment with a DMARD other than
leflunomide (three with methotrexate, two with hydroxy-
chloroquine), and two patients were excluded because
missing data prevented the DAS28 from being calculated
(VASgeneral health). Figure 3 shows the ROC curve for DAS28 in
relation to the A77 1726 concentration. The area under the
ROC curve was 0.50 (95% CI, 0.33 to 0.67) (p.0.1). Disease
activity was not significantly related to corticosteroid use
(p=0.1) or NSAID use (p.0.1).
DISCUSSION
Although our data showed no association between serum
concentrations of A77 1726 and disease activity, none of the
patients with low A77 1726 concentrations had a good
response according to the EULAR criteria.
Criteria for therapeutic drug monitoring
The International Association for Therapeutic Drug
Monitoring and Clinical Toxicology defines therapeutic drug
monitoring as ‘‘.. the measurement made in the laboratory of
a parameter which, with appropriate interpretation, will
directly influence prescribing procedures...’’14 Ensom et al15
have defined criteria for situations in which therapeutic drug
monitoring may be of value. These are: the drug has to be
part of the standard care for the indication; the drug can
easily be determined in biological matrices; the pharmaco-
logical effect of the drug is not directly measurable; the drug
has a small therapeutic window; and treatment with the drug
has to be continued for long enough to allow the effect of
dose adjustments to be determined on the basis of
therapeutic drug monitoring. Further, Ensom et al state that
there should be substantial inter- or intraindividual varia-
bility in pharmacokinetics and that there has to be a relation
between drug concentration levels and clinical efficacy. When
considering these criteria in relation to our present data, it is
apparent that therapeutic drug monitoring for leflunomide/
Table 1 Demographic and clinical characteristics
Characteristic
Number of patients 52
Age (years) 69 (12)
Female 67%
Time since diagnosis of rheumatoid arthritis (years) 11 (10)
Rheumatoid factor positive 71%
Leflunomide prescribed as first DMARD 21%
DMARDs before leflunomide (n) 2.0 (1.7)
Range 0 to 6
.1 Year of leflunomide treatment 90%
.2 Years of leflunomide treatment 60%
Duration of leflunomide use (days) 921 (299)
Range 136 to 1327
Prescribed daily leflunomide dose
10 mg 25%
20 mg 65%
Other* 10%
Concomitant corticosteroid use 44%
Concomitant other DMARD use 8%
Concomitant NSAID use 58%
Values are per cent, n, or mean (SD) as indicated.
*Range 5 to 15 mg leflunomide daily.
At least one active prescription at the point of sampling (low dose
salicylates (,100 mg daily) not included).
DMARD, disease modifying antirheumatic drug; NSAID, non-steroidal
anti-inflammatory drug.
Table 2 Demographic and clinical characteristics of the
population used for the analysis of the 28 joint disease
activity score response
Characteristic
Number of patients 25
Age (y) 68 (13)
Female 72%
Period since diagnosis of rheumatoid arthritis (y) 8 (7)
Rheumatoid factor positive 60%
DAS28 at baseline 5.1 (0.9)
DAS28 .5.1 at baseline (n) 13
DAS28 .3.2 and (5.1 at baseline (n) 12
Leflunomide prescribed as first DMARD 24%
Concomitant corticosteroid use 40%
Concomitant other DMARD use 0%
Concomitant NSAID use* 38%
Values are per cent, n, or mean (SD) as indicated.
*At least one active prescription at the point of sampling (low dose
(,100 mg daily) salicylates not included).
DAS28, 28 joint disease activity score; DMARD, disease modifying
antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug;
y, years.
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A77 1726 may useful in improving treatment efficacy for
several reasons: leflunomide is one of the DMARD options for
the long term treatment of rheumatoid arthritis but with
dose limiting toxicity; its efficacy cannot be determined early
after initiation of treatment or after dose adjustment; and
serum A77 1726 concentration can be determined by a
relatively simple chromatographic technique.
In relation to the last criterion mentioned by Ensom et al
(large variability in drug concentration levels), data from
clinical studies are scarce. However, large interindividual
variability of A77 1726 concentrations in a rheumatoid
population was shown in a recently published study, where
concentrations varied between 5 and 93 mg/l (n=12).16
Large interindividual variability of A77 1726 serum concen-
trations was also reported by Mladenovic et al.2 Our data
correlate well with these results. We conclude that lefluno-
mide does indeed meet that criterion.
It would be interesting to know whether the variability in
A77 1726 concentrations can be reduced by individualised
dosing based on patient characteristics. However, one study
on the influence of demographic variables found that none of
the variables studied affected steady state A77 1726 concen-
trations substantially.9 This leaves the possibility of adjusting
leflunomide treatment post hoc on the basis of therapeutic
drug monitoring.
In 1997, a pharmacokinetic/pharmacodynamic model for
predicting therapeutically active serum concentrations of
A77 1726 was published,9 based on data from phase I and II
studies. Using follow up results after six months of
leflunomide treatment and the Paulus criteria as the efficacy
end point, the investigators concluded that the maximum
probability of clinical success would be obtained by a dose
that maintains the steady state A77 1726 serum concentra-
tion above 13 mg/l. On the basis of this model they stated
that a daily leflunomide dose of 20 mg would result in steady
state A77 1726 concentrations above 13 mg/l in more than
99% of the patients. However, our data show that 12% of the
patients have A77 1726 concentrations of less than 13 mg/l
despite good compliance with treatment, defined as phar-
macy refill rates between 0.9 and 1.1. Using the previously
reported model,9 we conclude that in a significant proportion
of the rheumatoid population a daily leflunomide dose of 20
mg does not lead to steady state A77 1726 concentrations
with a maximum probability of clinical success.
On the other hand, our data support the conclusion9 that a
certain steady state concentration has to be exceeded in order
to obtain clinical success. The target concentration was
previously determined to be 13 mg/l,9 but our results suggest
a target concentration exceeding 18 mg/l for .90% sensitivity
or exceeding 16 mg/l for .99% sensitivity. Twenty eight per
cent of our patients had steady state A77 1726 serum
concentrations of less than 16 mg/l, representing approxi-
mately 50% of the patients with an inadequate response—
that is, moderate or non-responders according to the EULAR
criteria.
Some comments on the current study and the interpreta-
tion of the results are required. Our study was retrospective in
design and included a relatively small population for study of
the relation between steady state A77 1726 serum concentra-
tions and response. For this reason our results require
confirmation in a larger prospective study. Whether the
current design and sample size had an influence on the study
findings, apart from considerations of statistical power, is
unclear. There are indications that this may not be the case.
Attending rheumatologists were not aware of the serum
A77 1726 concentration at the time of blood sampling and or
when collecting data for calculating the DAS28, making
biased estimations of disease activity unlikely. Further, as
discussed earlier, our data are in accordance with the results
of Weber et al.9 Both studies found approximately the same
serum A77 1726 concentration cut off point for response to
treatment.
In our study 44% and 58% of the patients concomitantly
used corticosteroids and NSAIDs, respectively. As both
corticosteroids and NSAIDs may influence individual
DAS28 scores this concomitant treatment may have affected
our results. Although no relation between corticosteroid or
NSAID use and disease activity or response was found, our
study was not designed to correct for this potential
confounder.
No correlation between disease activity at the point of
sampling and serum A77 1726 concentrations was found.
One possible explanation for this is that disease activity at the
point of sampling was not stratified for baseline activity. A
DAS28 response which combines disease activity at the point
Table 3 262 table for response versus A77 1726 serum concentration
A77 1726 serum
concentration
DAS28 response category
TotalGood Non- or moderate
>16 mg/l 10 (40%)a 8 (32%)b 18 (72%)
,16 mg/l 0 (0%)c 7 (28%)d 7 (28%)
Total 10 (40%) 15 (60%) 25 (100%)
Values are n (%).
PPV (positive predictive value) = a/(a+b).
NPV (negative predictive value) = d/(c+d).
Likelihood ratio for positive test result = [a/(a+c)]/[b/(b+d)].
Likelihood ratio for negative test result = [c/(a+c)]/[d/(b+d)].
DAS28, 28 joint disease activity score.
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Figure 3 ROC (receiver operating characteristic) curve for the 28 joint
disease activity score response versus A77 1726 concentration
(AUC=0.50 (95% confidence interval, 0.33 to 0.67)). The dashed line is
the reference. AUC, area under the curve.
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of measurement and the change in disease activity from
baseline is an appropriate and validated end point for this
analysis. We used this analysis in the absence of published
data on a potential direct correlation between serum
A77 1726 concentrations and disease activity.
Furthermore, in our study no specific efforts were made to
optimise patient compliance with leflunomide treatment
besides routinely exercising good clinical practice.
Deviations from the prescribed daily dose are likely to affect
the steady state A77 1726 serum concentration. However, no
influence on the study results of deviations in treatment
compliance—that is refill rates outside the range of 0.9 to
1.1—is to be expected, for several reasons. First, no
correlation between refill rate and serum A77 1726 concen-
tration over the complete concentration range was detected.
Second, patients with serum A77 1726 concentrations
,13 mg/l and .100 mg/l all showed refill rates of between
0.93 and 1.06. Therefore, low or high refill rates were not
associated with serum A77 1726 concentrations in the lower
or upper concentration ranges.
Clinical implications
Our data show that disease activity assessed by DAS28
criteria was not correlated with serum A77 1726 concentra-
tions. When disease activity at baseline is taken into account,
there is a measure of response that allows evaluation of
leflunomide induced DAS28 responder categories. Our data
on the relation between A77 1726 concentrations and DAS28
response suggest possible future clinical applications for
therapeutic drug monitoring of A77 1726.
It would be interesting to know whether early decisions on
treatment withdrawal or continuation are improved under
non-blinded conditions—that is, whether decisions can be
based on the combination of insufficient response and a low
A77 1726 steady state serum concentration. Assuming
compliance with treatment and stable dosing, there is a
direct correlation between the duration of treatment, the
serum A77 1726 concentration at the point of assessment,
and the steady state A77 1726 serum concentration. This
leads to the hypothesis that a non-steady-state serum
A77 1726 concentration determined early in the course of
leflunomide treatment—for example after four weeks—may
well predict a patient’s response to therapy later on. Applying
this hypothesis to leflunomide treatment offers the theore-
tical opportunity to make early decisions based on non-
steady-state A77 1726 concentrations, and may prevent delay
before treatment is switched to more effective alternatives for
the individual patient. To what extent this approach will lead
to improvements in leflunomide treatment outcome has to be
the subject of further studies.
Second, one could speculate whether patients with an
inadequate clinical response to leflunomide treatment and a
low, subtherapeutic A77 1726 serum concentration (,16 mg/
l; 28% of the whole population in our study) will show an
improved response at increased daily leflunomide doses. As
A77 1726 shows linear pharmacokinetics (a linear relation
between dose rate and steady state serum concentrations), an
increased dose will lead to higher serum concentrations. With
a positive predictive value of 56%, not all patients with
A77 1726 concentrations >16 mg/l will become good respon-
ders according to DAS28 response criteria. We can put into
perspective the potential role of therapeutic drug monitoring
on the basis of our results as follows: from the fraction of
patients with a moderate or no response according to DAS28
criteria, approximately 50% will have a serum A77 1726
concentration of less than 16 mg/l. When increasing the dose
for these patients, we expect 56% to become DAS28 good
responders.
An additional point needs to be made about this approach.
Comparative studies on leflunomide in rheumatoid arthritis
have so far used a narrow dose range, varying between 5 and
25 mg daily.2 Despite its increased efficacy, a daily dose rate
of 25 mg is correlated with a higher incidence of adverse
effects.2 9 Whether toxicity at leflunomide doses of more than
20–25 mg/day remains a problem when the doses are
increased selectively in those with serum A77 1726 concen-
trations below 16–18 mg/l remains to be determined in
clinical studies.
Information on higher doses is available from studies in
the fields of rheumatology,17 18 transplantation medicine,19
and oncology.20 Recently, results were published on 11
patients with rheumatoid arthritis treated with 40 mg
leflunomide daily for at least three months.17 These patients
previously tolerated the 20 mg daily dose but still had active
disease. The investigators found that a daily dose of 40 mg
increased efficacy of the treatment in six of the 11 patients.
Four patients had mild and reversible adverse events after
the dose increase. Metzler et al18 described a prospective
study of leflunomide in 20 patients with Wegener’s granu-
lomatosis. Daily doses were increased stepwise to a max-
imum of 40 mg. These investigators concluded that the
safety profile of leflunomide was comparable with that
found in clinical trials despite the higher doses than those
used in the treatment of rheumatoid arthritis. Williams et al19
described a retrospective review of 53 liver or kidney trans-
plant recipients receiving leflunomide at maintenance doses
of 40 to 60 mg daily, after receiving loading doses of 1200–
1400 mg over seven days to achieve steady state A77 1726
serum concentra tions of 100 mg/l. In their review lefluno-
mide was well tolerated and dose limiting side effects
occurred in fewer than 15% of the patients when serum
drug levels were less than 80 mg/l. The investigators
concluded, on the basis of more than 300 days of follow
up, that patients can safely be given doses at this level.
Although not directly applicable to a population with
rheumatoid arthritis, these data are useful with regard to
the tolerability of doses above 20 mg/day.
Conclusions
We have shown that in a steady state there is no association
between disease activity and serum A77 1726 concentration.
However, lower subtherapeutic A77 1726 serum concentra-
tions are related to absence of response on leflunomide
therapy. These results support the conclusion that determi-
nation of serum A77 1726 concentrations may influence
prescribing procedures and provide the opportunity for
optimising leflunomide treatment.
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